Cargando…

How many migraine patients need prolonged (>1 year) preventive treatment? Experience with topiramate

The usual recommended duration of preventive treatment for migraine is 3–6 months. Our aim was to explore how many patients attending a specialised clinic need prolonged preventive treatment for longer than one year. Eighty consecutive migraine patients who received preventive treatment with topiram...

Descripción completa

Detalles Bibliográficos
Autores principales: Pascual, J., el Berdei, Y., Gómez-Sánchez, J. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476126/
https://www.ncbi.nlm.nih.gov/pubmed/17221343
http://dx.doi.org/10.1007/s10194-007-0351-x
_version_ 1782247053303218176
author Pascual, J.
el Berdei, Y.
Gómez-Sánchez, J. C.
author_facet Pascual, J.
el Berdei, Y.
Gómez-Sánchez, J. C.
author_sort Pascual, J.
collection PubMed
description The usual recommended duration of preventive treatment for migraine is 3–6 months. Our aim was to explore how many patients attending a specialised clinic need prolonged preventive treatment for longer than one year. Eighty consecutive migraine patients who received preventive treatment with topiramate for 3 months with good response and tolerability were included in this observational study. All patients continued on topiramate until they had completed 6 months, when this drug was stopped. Topiramate was reintroduced if there was a worsening. Topiramate was kept for 6 more months and then discontinued again. Those patients whose headaches became worse after this second withdrawal received topiramate again and were followed-up for at least half a year. Headaches did not worsen after the first withdrawal at 6 months in 40 patients (50%), while they clearly worsened in the remaining 40 patients. At the end of the first year only two patients out of these 40 (5%) discontinued topiramate and did not notice an increase in headache frequency after two months. In conclusion, around half of the patients attending a specialised clinic due to frequent headache need preventive treatment for more than one year. Our data suggest that the current practice recommending periods of preventive treatment of 3–6 months should be reconsidered for many patients.
format Online
Article
Text
id pubmed-3476126
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-34761262012-11-29 How many migraine patients need prolonged (>1 year) preventive treatment? Experience with topiramate Pascual, J. el Berdei, Y. Gómez-Sánchez, J. C. J Headache Pain Original The usual recommended duration of preventive treatment for migraine is 3–6 months. Our aim was to explore how many patients attending a specialised clinic need prolonged preventive treatment for longer than one year. Eighty consecutive migraine patients who received preventive treatment with topiramate for 3 months with good response and tolerability were included in this observational study. All patients continued on topiramate until they had completed 6 months, when this drug was stopped. Topiramate was reintroduced if there was a worsening. Topiramate was kept for 6 more months and then discontinued again. Those patients whose headaches became worse after this second withdrawal received topiramate again and were followed-up for at least half a year. Headaches did not worsen after the first withdrawal at 6 months in 40 patients (50%), while they clearly worsened in the remaining 40 patients. At the end of the first year only two patients out of these 40 (5%) discontinued topiramate and did not notice an increase in headache frequency after two months. In conclusion, around half of the patients attending a specialised clinic due to frequent headache need preventive treatment for more than one year. Our data suggest that the current practice recommending periods of preventive treatment of 3–6 months should be reconsidered for many patients. Springer-Verlag 2007-01-15 2007-04 /pmc/articles/PMC3476126/ /pubmed/17221343 http://dx.doi.org/10.1007/s10194-007-0351-x Text en © Springer-Verlag Italia 2007
spellingShingle Original
Pascual, J.
el Berdei, Y.
Gómez-Sánchez, J. C.
How many migraine patients need prolonged (>1 year) preventive treatment? Experience with topiramate
title How many migraine patients need prolonged (>1 year) preventive treatment? Experience with topiramate
title_full How many migraine patients need prolonged (>1 year) preventive treatment? Experience with topiramate
title_fullStr How many migraine patients need prolonged (>1 year) preventive treatment? Experience with topiramate
title_full_unstemmed How many migraine patients need prolonged (>1 year) preventive treatment? Experience with topiramate
title_short How many migraine patients need prolonged (>1 year) preventive treatment? Experience with topiramate
title_sort how many migraine patients need prolonged (>1 year) preventive treatment? experience with topiramate
topic Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476126/
https://www.ncbi.nlm.nih.gov/pubmed/17221343
http://dx.doi.org/10.1007/s10194-007-0351-x
work_keys_str_mv AT pascualj howmanymigrainepatientsneedprolonged1yearpreventivetreatmentexperiencewithtopiramate
AT elberdeiy howmanymigrainepatientsneedprolonged1yearpreventivetreatmentexperiencewithtopiramate
AT gomezsanchezjc howmanymigrainepatientsneedprolonged1yearpreventivetreatmentexperiencewithtopiramate